Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg)
19-2153
Phase 3 other active
Quick answer
Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg) for Critical Illness is a Phase 3 program (other) at UNITED THERAPEUTICS Corp with 2 ClinicalTrials.gov record(s).
Program details
- Company
- UNITED THERAPEUTICS Corp
- Indication
- Critical Illness
- Phase
- Phase 3
- Modality
- other
- Status
- active